Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0989788
Funder
Australian Research Council
Funding Amount
$108,481.00
Summary
Nuclear Magnetic Resonance Microimaging and Relaxometry Facility. Many of the research projects to be supported by the facility are dedicated to improving our understanding of conditions and diseases that detrimentally affect many in our community. Projects investigating Alzheimer's disease, the central nervous system and its ability to repair, cancer and associated therapeutic treatments are some of the areas that will benefit from access to this equipment. The new facility will also provide un ....Nuclear Magnetic Resonance Microimaging and Relaxometry Facility. Many of the research projects to be supported by the facility are dedicated to improving our understanding of conditions and diseases that detrimentally affect many in our community. Projects investigating Alzheimer's disease, the central nervous system and its ability to repair, cancer and associated therapeutic treatments are some of the areas that will benefit from access to this equipment. The new facility will also provide unique insights into aspects of fundamental plant biology, with implications for improving crop productivity and better managing our natural ecosystems. The community will also benefit from the development and testing within the facility of new diagnostic tools and markers for a range of diseases.Read moreRead less
Molecular response to interferon beta treatment in multiple sclerosis. Inteferon beta (IFNb) is the frontline drug for treatment of multiple sclerosis. However, in many patients this expensive drug provides no benefit, resulting in unnecessary, uncontrolled disease progression, and in a waste of many millions of dollars each year. A common explanation for this treatment failure is the development of neutralising antibodies (NABs). We will establish the prevalence and effects of NABs in Austra ....Molecular response to interferon beta treatment in multiple sclerosis. Inteferon beta (IFNb) is the frontline drug for treatment of multiple sclerosis. However, in many patients this expensive drug provides no benefit, resulting in unnecessary, uncontrolled disease progression, and in a waste of many millions of dollars each year. A common explanation for this treatment failure is the development of neutralising antibodies (NABs). We will establish the prevalence and effects of NABs in Australian patients, use novel techniques to identify biomarkers for IFNb response, evaluate the diagnostic and therapeutic value of the biomarkers, and develop a new test for NABs. Tailored use of this drug, and possible new therapeutic targets, will result, benefiting the patient and community.Read moreRead less